---
title: "四環醫藥回購 1,500 萬股  總價 2,176 萬元"
description: "四環醫藥公佈，10 月 17 日，從市場購回合共 1,500 萬股，每股平均價 1.4505 元，總購買價約 2,176 萬元。"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/261767839.md"
published_at: "2025-10-19T11:04:02.000Z"
---

# 四環醫藥回購 1,500 萬股  總價 2,176 萬元

> 四環醫藥公佈，10 月 17 日，從市場購回合共 1,500 萬股，每股平均價 1.4505 元，總購買價約 2,176 萬元。

四環醫藥 (00460.HK) 公佈，10 月 17 日，從市場購回合共 1,500 萬股，每股平均價 1.4505 元，總購買價約 2,176 萬元。

### Related Stocks

- [00460.HK - 四環醫藥](https://longbridge.com/zh-HK/quote/00460.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 10:00 ETExciting Update: Section El Beso Transitions to Exclusive Privilege Area at Ocean Coral & Turquesa | Ocean Signature Resorts announces that starting May 1, 2026, the El Beso section at Ocean Coral & Turquesa will transiti | [Link](https://longbridge.com/zh-HK/news/276348599.md) |
| Mikrobiomik secures approval for gut‑microbiota therapy for C difficile infection | Mikrobiomik has received approval in Spain for its oral therapy EUTEGRA (MBK-01) to treat Clostridioides difficile infec | [Link](https://longbridge.com/zh-HK/news/276345316.md) |
| Lightship Selects CRIO eSource and Site CTMS Platform to Support Scalable Trial Execution Across Its Expanding Site Network | Lightship Inc. has selected CRIO's integrated eSource and site CTMS platform to enhance trial execution across its expan | [Link](https://longbridge.com/zh-HK/news/276258845.md) |
| Genxone Offer For Microbiome Sequencing Services Chosen As Most Favorable In Tender | Genxone SA :OFFER FOR MICROBIOME SEQUENCING SERVICES CHOSEN AS MOST FAVORABLE IN TENDER BY NATIONAL INSTITUTE OF GERIATR | [Link](https://longbridge.com/zh-HK/news/276140489.md) |
| 09:15 ETAspen Publishing and Rhetoric Partner to Transform Legal Education Through AI-Powered Experiential Learning | Aspen Publishing and Rhetoric have partnered to enhance legal education by integrating AI-driven skills training into th | [Link](https://longbridge.com/zh-HK/news/276343563.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。